Under the Nov. 15 agreement, Celgene has agreed to sell its blockbuster psoriasis treatment, Otezla, to Amgen. Bristol-Myers Squibb is developing a competing treatment, which raised antitrust concerns about the Celgene acquisition.
Bristol-Myers Squibb has now satisfied all regulatory requirements to complete the merger, expected to close on Nov. 20. The drugmaker said it expects the Otezla divestiture to be completed promptly after the acquisition.
Read the full news release here.
More articles on pharmacy:
Drugmakers could lose $1T in sales and still be most profitable industry, analysis finds
CAR-T costs ‘not sustainable’ for hospitals, researchers say
How Walgreens, CVS see the future of pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
